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Clinical disease activity and acute phase reactant
levels are discordant among patients with active
rheumatoid arthritis: acute phase reactant levels
contribute separately to predicting outcome at
one year
Jonathan Kay1*, Olga Morgacheva2, Susan P Messing3, Joel M Kremer4, Jeffrey D Greenberg5, George W Reed6,
Ellen M Gravallese1 and Daniel E Furst2
Abstract
Introduction: Clinical trials of new treatments for rheumatoid arthritis (RA) typically require subjects to have an
elevated acute phase reactant (APR), in addition to tender and swollen joints. However, despite the elevation of
individual components of the Clinical Disease Activity Index (CDAI) (tender and swollen joint counts and patient
and physician global assessment), some patients with active RA may have normal erythrocyte sedimentation rate
(ESR) and/or C-reactive protein (CRP) levels and thus fail to meet entry criteria for clinical trials. We assessed the
relationship between CDAI and APRs in the Consortium of Rheumatology Researchers of North America (CORRONA)
registry by comparing baseline characteristics and one-year clinical outcomes of patients with active RA, grouped
by baseline APR levels.
Methods: This was an observational study of 9,135 RA patients who had both ESR and CRP drawn and a visit at
which CDAI was >2.8 (not in remission).
Results: Of 9,135 patients with active RA, 58% had neither elevated ESR nor CRP; only 16% had both elevated ESR
and CRP and 26% had either ESR or CRP elevated. Among the 4,228 patients who had a one-year follow-up visit,
both baseline and one-year follow-up modified Health Assessment Questionnaire (mHAQ) and CDAI scores were
lowest for patients with active RA but with neither APR elevated; both mHAQ and CDAI scores increased
sequentially with the increase in number of elevated APR levels at baseline. Each individual component of the CDAI
followed the same trend, both at baseline and at one-year follow-up. The magnitude of improvement in both CDAI
and mHAQ scores at one year was associated positively with the number of APRs elevated at baseline.
Conclusions: In a large United States registry of RA patients, APR levels often do not correlate with disease activity
as measured by joint counts and global assessments. These data strongly suggest that it is appropriate to obtain
both ESR and CRP from RA patients at the initial visit. Requiring an elevation in APR levels as a criterion for
inclusion of RA patients in studies of experimental agents may exclude some patients with active disease.
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Introduction
Among patients with rheumatoid arthritis (RA), disease
progression over time is difficult to predict. Demographic,
clinical, laboratory, and imaging parameters, both alone
and in combination, have been used to predict outcomes.
In some studies, erythrocyte sedimentation rate (ESR) ele-
vation correlated with disease outcomes such as joint ero-
sion [1-4] and Health Assessment Questionnaire Disability
Index (HAQ-DI) scores [5] whereas, in others, increased
C-reactive protein (CRP) levels (>20 mg/L) correlated bet-
ter with radiographic [6-10] and functional [9,11] out-
comes. However, when acute phase reactants (APRs) are
discordant, with elevation of only one (ESR or CRP), these
laboratory test results may not predict progression of
structural damage to joints [12]. Combining clinical mea-
sures with an APR level into composite disease activity in-
dices, such as the Disease Activity Score (DAS)28 or the
Simplified Disease Activity Index (SDAI), often predicts
structural and functional consequences [3,10,13-15]. How-
ever, joint destruction may continue to progress and func-
tional status may still deteriorate in RA patients treated
with nonbiologic disease-modifying antirheumatic drugs
(DMARDs), despite both improvement in clinical parame-
ters and persistent reduction of the ESR [12,16].
Clinical trials of new treatments for RA typically re-
quire subjects to have an elevated acute phase reactant,
in addition to tender and swollen joints. However, des-
pite the elevation of individual components of the Clin-
ical Disease Activity Index (CDAI) (tender and swollen
joint counts and patient and physician global assess-
ment), some patients with active RA may have normal
ESR and/or CRP levels [17-20] and thus fail to meet
entry criteria for clinical trials [21].
In this study, we assessed the relationship between
CDAI and APRs in the Consortium of Rheumatology
Researchers of North America (CORRONA) database, a
large United States registry of RA patients. We com-
pared the baseline characteristics and one-year clinical




The Clinical Disease Activity Index (CDAI) is a simpli-
fied disease activity score using a 28-joint count that in-
tegrates measures of physical examination, patient self-
assessment, and evaluator assessment. The CDAI score
(a scale of 0 to 76.0) is the numerical sum of the 28-
joint tender and swollen joint counts and the patient
and evaluator global health status, each assessed on a
10-cm visual analog scale [22]. It provides a validated in-
dication of RA disease activity, with scores of ≤2.8 sig-
nifying remission and scores of >22 connoting high
disease activity [23]. Because it requires no laboratory
test result, the CDAI is easy to calculate and allows for
immediate scoring.
The modified Health Assessment Questionnaire (mHAQ)
is a simplified version of the Health Assessment Question-
naire (HAQ). The HAQ consists of 20 questions that
inquire as to a patient’s ability to perform 20 activities of
daily living. These questions are grouped into eight cat-
egories. The mHAQ consists of eight questions, with one
taken from each category of the HAQ [24]. The total
mHAQ score is calculated as the mean of the individual
scores for each activity [25].
APR levels were considered to be elevated if the ESR
was >28 mm/h or if the CRP was >8 mg/L (>0.8 mg/dL).
Subjects
The CORRONA database from October 1, 2001, through
February 27, 2011, was used to identify subjects for this
study [26]. Ethical approval for participation in the
CORRONA registry was obtained from the respective
institutional review boards of participating academic re-
cruitment sites (Bassett Healthcare Network Institutional
Review Board, Cooperstown, NY; Baylor Research Insti-
tute Institutional Review Board, Dallas, TX; Colorado
Multiple Institutional Review Board, Aurora, CO;
Geisinger Health Systems Institutional Review Board,
Danville, PA; Hospital for Special Surgery Institutional
Review Board, New York, NY; Institutional Review
Board of the University of Michigan Medical School,
Ann Arbor, MI; Johns Hopkins Medicine Institutional
Review Board, Baltimore, MD; KUMC Human Subjects
Committee, Kansas City, KS; Medical College of Wisconsin/
Froedtert Hospital Institutional Review Board, Milwaukee,
WI; Meridian Health Institutional Review Board, Neptune,
NJ; Montefiore Medical Center Institutional Review
Board, Bronx, NY; North Shore-Long Island Jewish Insti-
tutional Review Board, Great Neck, NY; Northwestern
University Institutional Review Board, Chicago, IL; NYU
School of Medicine Institutional Review Board, New York,
NY; Ochsner Institutional Review Board, New Orleans,
LA; Rhode Island Hospital Institutional Review Board,
Providence, RI; Saint Louis University Institutional Review
Board, St. Louis, MO; Southern New Hampshire Medical
Center Institutional Review Board, Nashua, NH; SUNY
Downstate Institutional Review Board, Brooklyn, NY; UAB
Institutional Review Board for Human Use, Birmingham,
AL; University of California, Los Angeles Institutional Re-
view Board, Los Angeles, CA; University of California, San
Diego Institutional Review Board, San Diego, CA; Univer-
sity of Maryland, Baltimore Institutional Review Board,
Baltimore, MD; University of Massachusetts Medical
School Committee for the Protection of Human Subjects
in Research, Worcester, MA; University of Rochester Re-
search Subjects Review Board, Rochester, NY; University
of Wisconsin-Madison Health Sciences Institutional
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Review Board, Madison, WI; UT Southwestern Institutional
Review Board, Dallas, TX; Washington University in St.
Louis Institutional Review Board, St. Louis, MO) and from
the New England Institutional Review Board (Newton,
MA), a central institutional review board, for community-
based private recruitment sites. All patients provided
written informed consent prior to enrollment in the co-
hort, which allowed all subsequent analyses of the anon-
ymized data.
Patients were eligible for inclusion if they had a
rheumatologist-confirmed diagnosis of RA, but not of
psoriatic arthritis (PsA), and a visit with CDAI >2.8 (not
in remission) and both an ESR and CRP drawn at the
visit. A patient’s first visit in the CORRONA database
with CDAI >2.8 and reported APR information was se-
lected as the baseline visit. The CORRONA registry does
not mandate measurement of either APR, but records
the results of all laboratory studies ordered in the course
of routine clinical care. The baseline visit could be either
the enrollment visit into the CORRONA database or a
follow-up visit. Drug initiation was not a criterion. A
one-year follow-up visit was defined as a visit occurring
365 ± 60 days after the study baseline visit with both the
mHAQ and CDAI measured.
A sensitivity analysis was performed in the subset of
biologic-naïve RA patients, defined as those patients
who had not yet used any biologic agent before or at the
time of the baseline visit.
Statistical methods
Comparisons of outcomes among APR groups (neither
(zero) APR elevated, discordant APR levels (one APR el-
evated), or both (two) APR elevated) were assessed using
linear regression models for most continuous outcomes.
Log-linear models were used as noted in the tables for
outcomes with distributional properties less appropriate
for linear regression. Logistic regression models were
used for comparison of binary outcomes. In all cases P
values were generated using robust variance estimators
(sandwich estimators), which provide a method that is
not unduly affected by outliers or other small departures
from model assumptions. Comparisons of CDAI cat-
egory distributions were carried out using χ2 tests. No
adjustments were made for multiple comparisons. All
statistical analyses were carried out using SAS 9.3 on a




As of February 27, 2011, 27,412 patients with RA were
enrolled in the CORRONA registry. Of these, 9,135 pa-
tients had a visit with active RA (CDAI >2.8) and had
values recorded for both ESR and CRP and thus were
eligible for sample inclusion. Of the patients with active
RA, 5,295 (58.0%) had neither elevated ESR nor CRP.
Only 1,507 (16.5%) had elevated levels of both ESR and
CRP. Among the remaining 25.5% of patients, levels of
ESR and CRP were discordant: 1,212 (13.3%) had an ele-
vated ESR, but not CRP, and 1,121 (12.3%) had an ele-
vated CRP, but not ESR (Figure 1A).
Among the 9,135 patients, 4,031 (44.1%) were biologic-
naïve. The distribution of APR levels in this subset of
biologic-naïve patients was similar to that in the entire
group of 9,135 patients with active RA. Of the biologic-
naïve patients with active RA, 2,164 (53.7%) had neither
elevated ESR nor CRP. Only 765 (19.0%) had elevated
levels of both ESR and CRP. Among the remaining 27.3%
of patients, levels of ESR and CRP were discordant: 510
(12.6%) had an elevated ESR, but not CRP, and 592
(14.7%) had an elevated CRP, but not ESR (Figure 1B).
Of the 9,135 patients who were eligible for sample in-
clusion, 4,228 patients had a study visit in the 60-day
window of the one-year follow-up visit. The distribution
of APR levels at baseline, in this subset of patients with
one-year follow-up, was also similar to that in the entire
group of 9,135 patients with active RA. Of the patients
with active RA and a one-year follow-up visit, 2,520
(59.6%) had neither elevated ESR nor CRP. Only 650
(15.4%) had elevated levels of both ESR and CRP.
Among the remaining 25.0% of patients, levels of ESR
and CRP were discordant: 557 (13.2%) had an elevated
ESR, but not CRP, and 501 (11.8%) had elevated CRP, but
not ESR. For subsequent analyses, the 1,058 patients with
discordant APR levels (ESR >28 mm/h but CRP ≤8 mg/L
or CRP >8 mg/L but ESR ≤28 mm/h) were combined into
a single group (Figure 2).
The baseline mHAQ and CDAI scores were lowest for
patients with active RA but with neither APR elevated
(Table 1). Both mHAQ and CDAI scores increased se-
quentially as the number of elevated APR levels in-
creased (neither APR elevated, discordant APR levels, or
both APR elevated) at baseline. Each individual compo-
nent of the CDAI followed the same trend. Methotrexate
(MTX) use did not differ between groups. As the num-
ber of elevated baseline APRs increased, the proportion
of patients taking prednisone also increased (even after
adjustment for age). These trends were also observed
among the subset of biologic-naïve patients with active
RA (Table 2). In contrast to prednisone use, among all
9,135 patients with active RA, the proportion of patients
using biologics decreased with increasing number of ele-
vated baseline APRs (Table 1).
Distribution of disease activity levels at baseline was
significantly different (P <0.001) among the APR groups
(Figure 3). Patients with both APRs elevated had a 36.8%
rate of CDAI high disease activity, contrasted with 23.5%
in those with discordant APR levels and 16.7% in those
Kay et al. Arthritis Research & Therapy 2014, 16:R40 Page 3 of 10
http://arthritis-research.com/content/16/1/R40
ESR≤28 & CRP ≤0.8
5295
ESR≤28 & CRP >0.8 
1121
ESR>28 & CRP ≤ 0.8 
1212
ESR>28 & CRP >0.8 
1507
ESR≤28 & CRP ≤0.8
2164
ESR≤28 & CRP >0.8 
592
ESR>28 & CRP ≤ 0.8 
510




Figure 1 Distribution of acute phase reactant levels at baseline. Distribution of ESR and CRP levels at baseline (A) among the 9,135 patients
who had a visit with active RA (CDAI >2.8), and (B) among the 4,031 biologic-naïve patients who had a visit with active RA (CDAI >2.8). CDAI,
Clinical Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis.
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4,228 patients with 2 visits that fall 
into 12 month window
18,277 patients do not meet 
criteria: CDAI ≤2.8 or CRP or 
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9,135 patients with CDAI >2.8
& CRP/ESR values present
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Group 1
















Figure 2 Flow chart showing the distribution of study patients.
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with neither APR elevated. Rates of moderate disease ac-
tivity were similar among APR groups (32.8% for both
APR elevated, 33.8% for discordant APR levels, and
30.2% for neither APR elevated), but rates of CDAI low
disease activity differed (30.5% for both APR elevated
versus 42.6% for discordant APR levels, and 53.1% for
neither APR elevated). Disease activity levels at baseline
were distributed similarly among the APR groups in the
subset of biologic-naïve patients with active RA (data
not shown).
One-year follow-up
The mean mHAQ score at one-year follow-up was lowest
for patients with active RA and neither APR elevated and
was highest for those with both APRs elevated (Tables 3
and 4). Likewise, the mean CDAI score at one-year follow-
up was lowest for those patients with neither APR elevated
and was highest for those with both APRs elevated.
There was a positive association between the magnitude
of improvement in both CDAI and mHAQ scores at one
year and the number of APRs elevated at baseline. The
mean mHAQ score (± SD) decreased by 0.10 ± 0.43 for
those with both APRs elevated at baseline, but did not
change for those patients with neither APR elevated at
baseline (Table 5). The mean CDAI score (± SD) de-
creased by 7.68 ± 14.19 for those patients with both APRs
elevated, by 3.92 ± 12.37 for those with discordant APR
levels, and by only 2.40 ± 10.87 for those with neither APR
elevated (Table 5). A similar trend was observed for each
of the individual components of the CDAI, each of which
Table 1 Baseline characteristics by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 2,520 n = 1,058 n = 650
Age (years) 59.29 ± 13.22 62.21 ± 13.21 62.71 ± 13.34 <0.0001
Duration of RA (years) 11.01 ± 9.83 11.93 ± 10.68 10.91 ± 10.27 0.0406
One-year follow-up duration (days) 362.63 ± 30.51 363.33 ± 31.06 363.46 ± 32.03 0.7410
mHAQ 0.33 ± 0.40 0.45 ± 0.47 0.56 ± 0.54 <0.0001
CDAI 12.89 ± 10.15 15.18 ± 11.16 20.47 ± 14.68 <0.0001
Tender joints 3.73 ± 5.24 4.29 ± 5.40 6.30 ± 7.21 <0.0001*
Swollen joints 4.04 ± 5.13 4.80 ± 5.49 6.64 ± 6.42 <0.0001*
Patient global assessment 30.91 ± 23.82 36.35 ± 25.45 42.90 ± 27.56 <0.0001
MD global assessment 20.21 ± 16.61 24.67 ± 19.06 32.42 ± 22.50 <0.0001
Prednisone use 680 (26.98%) 341 (32.23%) 275 (42.31%) <0.0001
Methotrexate use 1,668 (66.19%) 698 (65.97%) 417 (64.15%) 0.6166
Biologic use 1,263 (50.12%) 447 (42.25%) 224 (34.46%) <0.0001
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease
Activity Index.
Table 2 Baseline characteristics of biologic-naïve patients by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 1,012 n = 487 n = 324
Age (years) 60.92 ± 13.49 63.24 ± 13.51 64.26 ± 12.79 <0.0001
Duration of RA (years) 8.62 ± 9.37 9.55 ± 10.46 7.47 ± 8.38 0.0074
One-year follow-up duration (days) 363.43 ± 29.79 364.78 ± 31.48 365.43 ± 31.72 0.5196
mHAQ 0.29 ± 0.38 0.38 ± 0.43 0.48 ± 0.53 <0.0001
CDAI 12.54 ± 10.18 14.61 ± 11.21 19.04 ± 14.91 <0.0001
Tender joints 3.53 ± 5.14 4.10 ± 5.46 5.68 ± 6.92 <0.0001*
Swollen joints 4.19 ± 5.41 4.76 ± 5.53 6.92 ± 6.73 <0.0001*
Patient global assessment 28.47 ± 23.70 34.31 ± 25.08 39.04 ± 27.26 <0.0001
MD global assessment 19.73 ± 15.59 23.22 ± 18.46 31.20 ± 23.03 <0.0001
Prednisone use 247 (24.41%) 138 (28.34%) 124 (38.27%) <0.0001
Methotrexate use 696 (68.77%) 322 (66.12%) 191 (58.95%) 0.0050
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease
Activity Index.
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was statistically significant at P <0.0001. The positive asso-
ciation between the magnitude of improvement in both
CDAI and mHAQ scores at one year and the number of
APRs elevated at baseline was also observed in the
subset of biologic-naïve RA patients, as was the simi-
lar trend for each of the individual components of
the CDAI (Table 6).
Discussion
In this study, we examined the relationship between APRs
and clinical outcome measures in patients with active RA.
The traditional expectation is that RA patients with CDAI
high disease activity might be more likely to have levels of
both APRs elevated, whereas those with CDAI low disease
activity might not have elevation of either APR. However,
both APRs were elevated in only 26.3% of patients with
CDAI high disease activity in our cohort, whereas neither
APR was elevated in 46.3%; conversely, 32.7% of those
with CDAI low disease activity had at least one APR ele-
vated and 10.0% had both APRs elevated (Figure 3). These
findings imply that APR levels, which traditionally are
measured in most randomized clinical trials, often do not
reflect disease activity as measured by joint counts and
global assessments. When only one APR was assessed at
the initial evaluation, we observed that an elevated level
might not be detected in up to 73.7% (670) of the patients
with high CDAIs and up to 84.0% (1,118) of those with





























Figure 3 Distribution of acute phase reactant groups among the CDAI disease activity levels at baseline. Distribution of acute phase
reactant groups among the CDAI disease activity levels at baseline in the 4,228 RA patients with a one-year follow-up visit. Percentages within
the bars indicate relative proportions of subjects within each CDAI disease activity level. Numbers in parentheses within the bars enumerate sub-
jects in each group. CDAI, Clinical Disease Activity Index; RA, rheumatoid arthritis; LDA, low disease activity; MDA, moderate disease activity; HDA,
high disease activity.
Table 3 Clinical and functional status at one-year follow-up by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 2,520 n = 1,058 n = 650
mHAQ 0.34 ± 0.42 0.42 ± 0.49 0.47 ± 0.54 <0.0001
CDAI 10.45 ± 10.74 11.34 ± 10.72 12.75 ± 11.87 <0.0001
Tender joints 3.04 ± 5.36 3.01 ± 4.88 3.55 ± 5.87 0.1125*
Swollen joints 2.93 ± 4.65 3.31 ± 4.72 4.03 ± 5.27 <0.0001*
Patient global assessment 28.50 ± 24.81 31.53 ± 26.13 31.74 ± 26.68 <0.0007
MD global assessment 16.02 ± 16.31 18.23 ± 17.19 19.73 ± 19.73 <0.0001
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
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of identifying an elevated APR in patients with active RA
is greater when both the ESR and CRP are obtained at the
baseline evaluation.
Discordance between APRs has also been observed in
other studies that correlated clinical characteristics with
laboratory findings [17,19,20]. Graf and colleagues found
a weak correlation between CRP levels and CDAI scores
(r = 0.18, P = 0.027) among 151 patients with RA [19].
Although all seven of their patients who were in CDAI
remission had CRP <8 mg/L, only 46 (33.3%) of the 138
patients with CDAI >2.8 had CRP >8 mg/L. Crowson and
coworkers also found a weak correlation between APRs
and CDAI scores (r = 0.29 for CRP and r = 0.28 for ESR)
among 1,247 RA patients [17]. DAS28, which includes
an APR in its scoring, correlated more closely with APRs,
(r = 0.48 for CRP and r = 0.53 for ESR), as expected. In
another study of 689 patients with RA, Wolfe and collabo-
rators found 41% agreement between DAS28 and ESR
(Kendall's tau-a 0.41; 95% CI: 0.37 to 0.45) [20].
In our cohort of patients with active RA, as defined by
CDAI >2.8, the number of elevated APRs (0, 1, or 2) often
did not reflect disease activity at the time of the baseline
measure: 46.3% had neither APR elevated with a high
CDAI and 32.7% had elevation of at least one APR, despite
being in a CDAI low disease activity state (Figure 3). Both
APRs were elevated in only 26.3% of those with high base-
line CDAIs. Crowson and coworkers also observed a poor
correlation between the number of swollen joints and APR
elevation [17]. Discordance between clinical parameters
and laboratory values may be due, at least in part, to the
lower sensitivity of detecting subtle joint inflammation
during the clinical examination of patients with RA [27].
APR elevation may also reflect inflammation in areas
other than the joints [28]. Thus, in many RA patients,
APR values alone may not be accurate indicators of dis-
ease activity.
We observed an association between the numbers of
APR elevated at baseline and the CDAI or mHAQ re-
sponse at one year. The greatest decrease in CDAI was ob-
served when both APRs were elevated at baseline and the
smallest when neither APR was elevated. An intermediate
decrease was observed when APR levels were discordant.
Similar ‘APR-dependent’ associations were found between
each of the individual components of CDAI, except for
the tender joint count (Tables 5 and 6). The number of
tender joints can be influenced by factors other than joint
inflammation, including osteoarthritis of the examined
joints or pain amplification in central sensitization syn-
dromes, thereby rendering it less reflective of RA disease
activity [29]. The change in mHAQ score also correlated
with the number of APRs elevated at baseline, although
less consistently than did the change in CDAI score
(Tables 5 and 6).
As expected, there was an inverse relationship between
APRs and the use of biologics. However, there was a dir-
ect relationship between APRs and the use of prednis-
one: the greatest proportion of patients using prednisone
was in the group of patients with both APRs elevated.
Table 4 Clinical and functional status at one-year follow-up by APR levels among biologic-naïve patients
Neither APR elevated APR levels discordant Both APR elevated P value
n = 1,012 n = 487 n = 324
mHAQ 0.28 ± 0.40 0.32 ± 0.43 0.34 ± 0.46 0.0623
CDAI 9.65 ± 10.11 9.75 ± 9.81 10.85 ± 11.17 0.2243
Tender joints 2.64 ± 4.93 2.41 ± 4.33 2.83 ± 5.17 0.4378*
Swollen joints 2.90 ± 4.66 2.91 ± 4.54 3.52 ± 5.04 0.1299*
Patient global assessment 26.23 ± 24.77 28.36 ± 25.62 28.68 ± 26.53 0.1149
MD global assessment 14.52 ± 14.82 15.61 ± 15.38 16.43 ± 15.85 <0.0001
Biologic use 150 (14.84%) 83 (17.08%) 67 (20.68%) 0.0437
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
Table 5 Change in clinical and functional status between baseline and one year by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 2,520 n = 1,058 n = 650
mHAQ 0.01 ± 0.31 −0.03 ± 0.40 −0.10 ± 0.43 <0.0001
CDAI −2.40 ± 10.87 −3.92 ± 12.37 −7.68 ± 14.19 <0.0001
Tender joints −0.69 ± 5.48 −1.28 ± 5.81 −2.75 ± 6.98 <0.0001
Swollen joints −1.12 ± 5.11 −1.49 ± 5.53 −2.58 ± 5.95 <0.0001
Patient global assessment −2.38 ± 25.21 −4.90 ± 27.78 −11.29 ± 30.11 <0.0001
MD global assessment −4.21 ± 17.30 −6.45 ± 19.78 −12.57 ± 23.19 <0.0001
APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
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Thus, the relationships of APRs to the use of prednisone
and to the use of biologics move in opposite directions.
This may reflect both the effectiveness of biologics in re-
ducing APR levels and the propensity of physicians to
use corticosteroids to treat patients with active RA. No
difference was observed among patients taking MTX,
consistent with the previously reported weak effect of
MTX on APRs [30,31].
This was an observational study of data from a registry,
in which clinical measurements were mandated but la-
boratory studies were not and were ordered according
to physician practice style. Thus, not all patients in the
CORRONA database had values available for both ESR
and CRP. However, the demographic characteristics of the
patients who did not have either APR measured were simi-
lar to those for whom an ESR or CRP level had been
obtained. Among 92,062 visits for 17,445 RA patients in
the CORRONA database, an APR was measured at 47,164
(51.2%) of the visits. There was no association between
whether or not an APR level had been assessed and age,
sex, or measures of disease activity or physical function [32].
For our study, we chose cutoff values of 28 mm/h for
ESR and 8 mg/L for CRP in patients with active RA,
since these APR values have typically been used as entry
criteria for clinical trials of novel therapies for RA. How-
ever, the cutoff value for the ESR is above the upper
limit of normal used by clinical laboratories for this test.
Moreover, in clinical practice, rheumatologists prefer to
see APR levels well below the upper limit of normal
when treating patients with RA. Thus, the proportion of
patients with ‘normal’ levels of both APR might have
been smaller if a lower cutoff value for the ESR had been
used. However, our finding that disease activity measures
correlate weakly with APR elevation underscores the
limitations of using minimum values of 28 mm/h for
ESR or 8 mg/L for CRP, in addition to swollen and ten-
der joint counts, as entry criteria for clinical trials of
novel therapies for RA, since the majority of patients
with active RA have levels of both ESR and CRP below
these threshold values. In addition, there was a possible
floor effect among patients with fewer APRs elevated at
baseline: patients who are doing better have less ‘room
for improvement’ and those who start from a ‘worse
place’ may make greater gains.
For most patients in our study, CDAI was responsive
to change and can serve as a good indicator of the de-
gree of joint inflammation. A better understanding of
the relationship between APRs and disease activity, as
measured by the CDAI, will allow for a more informed
use of these measures in clinical practice and in clinical
trials of novel therapeutic agents. In addition, our obser-
vation that elevation of APR levels is often discordant
with what clinicians can measure in the clinic implies
that systemic inflammation may continue, even while
joint swelling and tenderness are ‘controlled’. It is also
possible that this systemic inflammation involves areas
other than the joints [28].
Normalization of CRP levels in subjects at risk for
heart disease is associated with a significantly lower
number of cardiovascular events [28]. This same comor-
bidity is the chief cause of premature mortality in pa-
tients with RA [33]. It therefore follows that elucidating
the long-term relationship between APRs and cardiovas-
cular disease in patients with RA will add greatly to our
understanding of the overall relevance of these measures
in clinical domains other than those typically measured
in daily practice and in randomized clinical trials in
rheumatology. These relationships likely will become
clearer with continued observation of these variables
among large numbers of patients followed in long-term
disease registries.
Conclusions
Obtaining both ESR and CRP in a patient with active
RA increases the yield of identifying an elevated APR
level. However, APR levels often do not reflect disease
activity, as measured by joint counts and global assess-
ments. Change in CDAI and mHAQ at one year is asso-
ciated with the number of APRs elevated at baseline.
The normal APR levels present in over half of patients
with active joint disease, as determined by CDAI, in a
large United States registry of RA patients would exclude
Table 6 Change in clinical and functional status between baseline and one year by APR levels among biologic-naïve
patients
Neither APR elevated APR levels discordant Both APR elevated P value
n = 1,012 n = 487 n = 324
mHAQ 0.00 ± 0.29 −0.06 ± 0.35 −0.14 ± 0.41 <0.0001
CDAI −2.91 ± 10.92 −4.93 ± 12.35 −8.16 ± 13.53 <0.0001
Tender joints −0.91 ± 5.54 −1.69 ± 5.88 −2.82 ± 6.64 <0.0001
Swollen joints −1.28 ± 5.11 −1.85 ± 5.60 −2.81 ± 5.78 <0.0001
Patient global assessment −2.14 ± 26.41 −6.00 ± 27.96 −10.58 ± 30.18 <0.0001
MD global assessment −5.23 ± 16.46 −7.62 ± 19.49 −14.62 ± 22.91 <0.0001
APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
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these patients from participation in many clinical trials of
novel therapies for RA. Thus, clinical trials of novel ther-
apies for RA might use CDAI >10 (the cutoff for moderate
disease activity), rather than elevated APR, as a criterion
for entry. These changes might have the effect of increas-
ing enrollment while providing a more representative
population of patients for clinical trials. The long-term im-
plications of discordance in APRs will need to be studied
further in large populations of RA patients followed pro-
spectively over prolonged time intervals.
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